Latest From Scrip Team
Pipeline Watch: Five Approvals And 15 Phase III Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Executives On The Move: AVEO Pharmaceuticals, Everest Medicines and More
Recent executive changes in the industry include C-suite changes at Aveo Pharmaceuticals and Scandion Oncology. Meanwhile, new directors were appointed at Akston Biosciences and Everest Medicines.
Pipeline Watch: 10 Approvals And Nine Phase III Trial Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Executives On The Move: Beijing Konruns Pharmaceutical, KemPharm and More
Recent executive changes in the industry include C-suite changes at KemPharma and Imago BioSciences. Meanwhile, new directors were appointed at Beijing Konruns Pharmaceutical and Ventyx Biosciences.
Pipeline Watch: Five Approvals And Eight Phase III Trial Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
The Best Of J.P. Morgan – Valuations, Deals And The IRA
Scrip reporters spoke with many biopharma industry execs and observers during the J.P. Morgan Healthcare Conference in San Francisco – here are some of the highlights from interviews and presentations.